ClinicalTrials.gg
CompletedNCT02630966ENTERPRISEUpdated Nov 19, 2019Results posted

Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease

A Phase 4 interventional study of Vedolizumab and Placebo in Crohn's Disease, sponsored by Takeda. Completed at 18 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing vedolizumab in Crohn Disease — 10 open to participants now, 12 under way, 7 of them phase 3. vedolizumab · Crohn Disease.

Enrollment
33rd of 39
34 · median 101
Started
2016
with 6 others
Phase 4
14 of 39
3 open now
Registered
12th of 39
by date
Lead sponsor
25 of 39
Takeda

Among the 39 studies testing vedolizumab in Crohn Disease, this one is the 33rd largest by enrollment, is one of 7 that started in 2016, is one of 14 in phase 4, and was the 12th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

10 of the 39 studies testing vedolizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About vedolizumab

vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing vedolizumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the percentage of participants with perianal fistula healing at Week 30 in 2 different dose regimens of vedolizumab intravenous (IV) 300 milligram (mg) in participants with fistulizing Crohn's disease (CD).

Read the detailed description

The drug being tested in this study is called vedolizumab IV. Vedolizumab IV is being tested to treat people who have fistulizing CD. This study will look at fistula healing in people who take vedolizumab IV.

The study is planned to enroll approximately 100 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • Group 1: Vedolizumab IV 300 mg dose at Weeks 0, 2, 6, 14 and 22, and a placebo infusion at Week 10 (dummy inactive infusion - this is a solution that looks like the study drug but has no active ingredient).
  • Group 2: Vedolizumab IV 300 mg dose at Weeks 0, 2, 6, 10, 14 and 22.

This multi-center trial will be conducted worldwide. The overall time to participate in this study from screening to 18 weeks after the last dose is 44 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone 6 months after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Drug therapy
  • Fistulizing Crohn´s disease
  • Perianal Fistula
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative has signed and dated a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has a diagnosis of CD established at least 3 months prior to randomization by clinical and endoscopic evidence and corroborated by a histopathology report.
  4. Has a diagnosis of a minimum of 1 perianal draining fistula of at least 2 weeks duration as a complication of moderately to severely active CD, as identified on magnetic resonance image (MRI) at Screening. Other types of fistulae (enterocutaneous, abdominal) except rectovaginal fistulae are permitted, but the number of perianal draining fistulae is limited to 3.
  5. All countries except France: The participant, historically, had an inadequate response with, lost response to, or was intolerant to either conventional therapy or a tumor necrosis factor-alpha (TNF-α) antagonist for their underlying CD (does not require treatment failure for currently active draining fistula).

    France only: The participant, historically, failed (ie, had an inadequate response with, lost response to, or was intolerant to) infliximab for treatment of their underlying CD or fistulizing CD.

  6. If the participant had noncutting perianal seton placement as part of standard care, seton must be removed by Week 14 of the study.

Exclusion criteria

Exclusion Criteria:

  1. Has a diagnosis of ulcerative colitis or indeterminate colitis.
  2. Has a perianal abscess greater than (>) 2 centimeter (cm) or an abscess that the investigator feels requires drainage based on either clinical assessment or MRI.
  3. Has a Crohn's Disease Activity Index (CDAI) score >400.
  4. Has an ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
  5. Has significant anal or rectal stenosis.
  6. Has active or latent tuberculosis (TB), regardless of treatment history.
  7. Has evidence of active Clostridium difficile (C. difficile) infection or is having treatment for C. difficile infection or other intestinal pathogens during Screening.
  8. Has current rectovaginal fistula.
  9. Currently has more than 3 draining perianal fistulae. Note: Other protocol-defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Group 1: Vedolizumab IV 300 mg + Placebo

    Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 14, and 22, and vedolizumab placebo-matching, IV infusion once, at Week 10 to maintain the blind.

    Drug: Vedolizumab · Drug: Placebo

  • Experimental
    Group 2: Vedolizumab 300 mg

    Vedolizumab 300 mg, IV infusion, once, at Weeks 0, 2, 6, 10, 14, and 22.

    Drug: Vedolizumab

Interventions

  • Vedolizumab 300 mg IV infusion

    Also known as: Entyvio, MLN0002, Kynteles

  • DrugPlacebo

    0.9% sodium chloride IV infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline)

    Closed fistulae are no longer draining despite gentle finger compression.

    Time frame: Baseline, Week 30

Secondary outcomes

  1. Percentage of Participants With at Least 50% Reduction of From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline) at Both Weeks 22 and 30

    Closed fistulae are no longer draining despite gentle finger compression.

    Time frame: Weeks 22 and 30

  2. Percentage of Participants With 100% Perianal Fistulae Closure (of the Fistulae Draining at Baseline)

    Closed fistulae are no longer draining despite gentle finger compression.

    Time frame: Week 30

  3. Time to First Perianal Fistulae Closure (of Those Fistulae Draining at Baseline)

    Closed fistulae are no longer draining despite gentle finger compression.The time to first fistula closure was analyzed descriptively using Kaplan-Meier product limit methods, with participants for which no fistula closure is reported being censored at the time of their last fistulae assessment or date of last record (Week 30 or early discontinuation). Estimated median time to fistula closure (and 95%CI) are reported.

    Time frame: Up to Week 30

  4. Time to Last (100%) Perianal Fistulae Closure (of Those Fistulae Draining at Baseline)

    Closed fistulae are no longer draining despite gentle finger compression. The time to first fistula closure was analyzed descriptively using Kaplan-Meier product limit methods, with participants for which no fistula closure is reported being censored at the time of their last fistulae assessment or date of last record (Week 30 or early discontinuation). Estimated median time to fistula closure (and 95%CI) are reported.

    Time frame: Up to Week 30

  5. Duration of Perianal Fistulae Response (of Those Fistulae Draining at Baseline)

    Duration of fistula response was measured by number of days with/without drainage. Duration of perianal fistula response (days) was derived as the sum of days with perianal fistula response between Day 1 and the end of the study (Week 30 or early discontinuation). Perianal fistula response is defined as reduction in the number of draining perianal fistulae (of those draining at Baseline) draining of at least 50%.

    Time frame: Up to Week 30

07

Results

Posted Sep 25, 2019
Limitations and caveats
Takeda decided to close enrollment after randomizing 34 participants.Decision was taken due to challenges in recruitment and was not related to any safety concerns.Participants randomized before enrollment closure continued participation as planned.

Participant flow

Participants took part in the study at 13 investigative sites in Canada, France, Italy, the Netherlands, Spain, the United Kingdom, and the United States from 10 August 2016 to 14 November 2018.

Participant flow — Overall Study
MilestoneGroup 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mg
Started1618
Completed1410
Not completed28
Withdrew: Adverse event13
Withdrew: Significant protocol deviation02
Withdrew: Voluntary withdrawal11
Withdrew: Lack of efficacy02

Outcome measures

PrimaryPercentage of Participants With at Least 50% Reduction From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline)

Closed fistulae are no longer draining despite gentle finger compression.

Time frame:
Baseline, Week 30
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline)
percentage of participantsGroup 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mg
Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline)75.0 (50.5 to 99.5)75.0 (45.0 to 100.0)
SecondaryPercentage of Participants With at Least 50% Reduction of From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline) at Both Weeks 22 and 30

Closed fistulae are no longer draining despite gentle finger compression.

Time frame:
Weeks 22 and 30
Reported as:
Number · percentage of participants
Percentage of Participants With at Least 50% Reduction of From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline) at Both Weeks 22 and 30
percentage of participantsGroup 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mg
Percentage of Participants With at Least 50% Reduction of From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline) at Both Weeks 22 and 3072.7 (46.4 to 99.0)62.5 (24.5 to 91.5)
SecondaryPercentage of Participants With 100% Perianal Fistulae Closure (of the Fistulae Draining at Baseline)

Closed fistulae are no longer draining despite gentle finger compression.

Time frame:
Week 30
Reported as:
Number · percentage of participants
Percentage of Participants With 100% Perianal Fistulae Closure (of the Fistulae Draining at Baseline)
percentage of participantsGroup 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mg
Percentage of Participants With 100% Perianal Fistulae Closure (of the Fistulae Draining at Baseline)58.3 (30.4 to 86.2)62.5 (24.5 to 91.5)
SecondaryTime to First Perianal Fistulae Closure (of Those Fistulae Draining at Baseline)

Closed fistulae are no longer draining despite gentle finger compression.The time to first fistula closure was analyzed descriptively using Kaplan-Meier product limit methods, with participants for which no fistula closure is reported being censored at the time of their last fistulae assessment or date of last record (Week 30 or early discontinuation). Estimated median time to fistula closure (and 95%CI) are reported.

Time frame:
Up to Week 30
Reported as:
Median · days
Time to First Perianal Fistulae Closure (of Those Fistulae Draining at Baseline)
daysGroup 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mg
Time to First Perianal Fistulae Closure (of Those Fistulae Draining at Baseline)30.5 (15.0 to 71.0)159.0 (16.0 to NA)
SecondaryTime to Last (100%) Perianal Fistulae Closure (of Those Fistulae Draining at Baseline)

Closed fistulae are no longer draining despite gentle finger compression. The time to first fistula closure was analyzed descriptively using Kaplan-Meier product limit methods, with participants for which no fistula closure is reported being censored at the time of their last fistulae assessment or date of last record (Week 30 or early discontinuation). Estimated median time to fistula closure (and 95%CI) are reported.

Time frame:
Up to Week 30
Reported as:
Median · days
Time to Last (100%) Perianal Fistulae Closure (of Those Fistulae Draining at Baseline)
daysGroup 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mg
Time to Last (100%) Perianal Fistulae Closure (of Those Fistulae Draining at Baseline)45.0 (15.0 to 155.0)159.0 (16.0 to NA)
SecondaryDuration of Perianal Fistulae Response (of Those Fistulae Draining at Baseline)

Duration of fistula response was measured by number of days with/without drainage. Duration of perianal fistula response (days) was derived as the sum of days with perianal fistula response between Day 1 and the end of the study (Week 30 or early discontinuation). Perianal fistula response is defined as reduction in the number of draining perianal fistulae (of those draining at Baseline) draining of at least 50%.

Time frame:
Up to Week 30
Reported as:
Median · days
Duration of Perianal Fistulae Response (of Those Fistulae Draining at Baseline)
daysGroup 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mg
Duration of Perianal Fistulae Response (of Those Fistulae Draining at Baseline)158.5 (0 to 202)33.5 (0 to 203)

Adverse events

Collected over Up to approximately 44 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: Vedolizumab IV 300 mg + Placebo0/16 (0%)4/16 (25%)15/16 (93.8%)
Group 2: Vedolizumab 300 mg0/18 (0%)3/18 (16.7%)17/18 (94.4%)
Most frequent serious events
Most frequent serious events
EventGroup 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mg
Anal abscessInfections and infestations3/160/18
Crohn's diseaseGastrointestinal disorders1/161/18
Ileal stenosisGastrointestinal disorders1/160/18
Abdominal infectionInfections and infestations1/160/18
HyperpyrexiaGeneral disorders0/161/18
ArthralgiaMusculoskeletal and connective tissue disorders0/161/18
Most frequent other events
Showing 10 of 89
Most frequent other events
EventGroup 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mg
Crohn's diseaseGastrointestinal disorders1/165/18
ArthralgiaMusculoskeletal and connective tissue disorders1/165/18
Abdominal painGastrointestinal disorders4/162/18
PyrexiaGeneral disorders2/164/18
HeadacheNervous system disorders2/164/18
Anal abscessInfections and infestations3/160/18
ProctalgiaGastrointestinal disorders2/160/18
Anal fistulaGastrointestinal disorders2/162/18
MyalgiaMusculoskeletal and connective tissue disorders2/160/18
VomitingGastrointestinal disorders0/162/18

Baseline characteristics

The Safety Analysis Set included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Group 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mgTotal
Mean35.1 ± 10.3535.1 ± 10.6735.1 ± 10.36
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mgTotal
Female6713
Male101121
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mgTotal
Hispanic or Latino000
Not Hispanic or Latino235
Unknown or Not Reported141529
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mgTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American101
White121527
More than one race000
Unknown or Not Reported235
Region of Enrollment
Region of Enrollment(Participants)Group 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mgTotal
Canada101
France235
Italy5611
Netherlands235
Spain325
United Kingdom112
United States235
Height
Height(centimeter (cm))Group 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mgTotal
Mean170.1 ± 6.35176.4 ± 10.38173.4 ± 9.17
Weight
Weight(kilograms (kg))Group 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mgTotal
Mean73.65 ± 15.98668.36 ± 14.66170.85 ± 15.299
Body Mass Index (BMI)
Body Mass Index (BMI)(kg per square meter (kg/m^2))Group 1: Vedolizumab IV 300 mg + PlaceboGroup 2: Vedolizumab 300 mgTotal
Mean25.40 ± 5.08021.84 ± 3.58023.52 ± 4.646

1 further baseline measures are reported on the registry.

08

Study locations

18 sites
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212-1375, United States
  • Texas Digestive Disease Consultants
    Southlake, Texas 76092, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • University of Calgary
    Calgary, Alberta T2N 4Z6, Canada
  • GIRI (GI Research Institute)
    Vancouver, British Columbia V6Z 2K5, Canada
  • CHRU de Lille - Hopital Claude Huriez
    Lille cedex, 59037, France
  • Hopital l'Archet II
    Nice Cedex 3, 06202, France
  • CHU de Rennes - Hopital de Pontchaillou
    Rennes cedex 9, 35033, France
  • Hopital de Brabois
    Vandoeuvre les Nancy, 54511, France
  • Azienda Ospedaliera S. Orsola-Malpighi
    Bologna, 40138, Italy
  • Istituto Clinico Humanitas IRCCS
    Milan, 20089, Italy
  • Academic Medical Center
    Amsterdam, 1105 AZ, Netherlands
  • Leids Universitair Medisch Centrum
    Leiden, 2333 ZA, Netherlands
  • Erasmus MC
    Rotterdam, 3015 CE, Netherlands
  • Hospital Clinic Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario y Politecnico La Fe
    Valencia, 46026, Spain
  • Nottingham University Hospitals NHS Trust
    Nottingham, NG7 2UH, United Kingdom
  • John Radcliffe Hospital
    Oxford, OX3 9DU, United Kingdom
09

References and documents

Publications

  • Schwartz DA, Peyrin-Biroulet L, Lasch K, Adsul S, Danese S. Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study. Clin Gastroenterol Hepatol. 2022 May;20(5):1059-1067.e9. doi: 10.1016/j.cgh.2021.09.028. Epub 2021 Sep 29. PubMed 34597729 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Sep 2018, 24 months.

Results were first posted in Sep 2019, 1 year after primary completion.

Of 70 phase 4 interventional studies under Crohn Disease, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 68. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2015
First posted
Dec 15, 2015
StartActual
Aug 10, 2016
Primary completionActual
Sep 4, 2018
CompletionActual
Nov 14, 2018
Results first posted
Sep 25, 2019
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02630966
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Dec 15, 2015
Start date
Aug 10, 2016
Primary completion
Sep 4, 2018
Completion
Nov 14, 2018
Results posted
Sep 25, 2019
Last update
Nov 19, 2019

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion